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ABSTRACT
Objective: Obstructive sleep apnoea (OSA), atrial
fibrillation (AF) and sudden cardiac death (SCD) may
occur concomitantly, and are of considerable
epidemiological interest, potentially leading to
morbidity and mortality. Effective treatment of OSA
with continuous positive airway pressure (CPAP) could
prevent progression and/or recurrence of AF and
factors leading to SCD. Recently, a randomised
controlled trial showed a statistically and clinically
significant prolongation of measures of cardiac
repolarisation after CPAP withdrawal in symptomatic
patients with moderate to severe OSA. Whether or not
CPAP therapy improves ECG risk markers of AF and
SCD in patients with minimally symptomatic OSA as
well, is unknown.
Methods: 3 centres taking part in the MOSAIC
(Multicentre Obstructive Sleep Apnoea Interventional
Cardiovascular) trial randomisd 303 patients with
minimally symptomatic OSA to receive either CPAP or
standard care for 6 months. Treatment effects of CPAP
on P-wave duration, P-wave dispersion, QT interval, QT
dispersion, Tpeak-to-Tend (TpTe) and TpTe/QT ratio
were analysed.
Results: Participants were primarily men (83%). Mean
age was 57.8 (7.2) and mean ODI (Oxygen
Desaturation Index) at baseline was 13.1/h (12.3). Full
12-lead ECG data was available in 250 patients. Mean
(SD) baseline intervals of P-wave duration, P-wave
dispersion, QTc interval, QT dispersion, TpTe and TpTe/
QT ratio in ms were 87.4 (8.3), 42.3 (11.9), 397.8
(22.7), 43.1 (16.7), 73.5 (13.7) and 0.19 (0.0),
respectively. No treatment effect of CPAP on risk
markers for AF and SCD was found.
Conclusions: There seems to be no effect of CPAP on
ECG measures of arrhythmia risk in patients with
minimally symptomatic OSA.
Trial registration number: ISRCTN34164388; Post-
results.
INTRODUCTION
Up to 30% of middle-aged adults are
affected by minimally symptomatic obstruct-
ive sleep apnoea (OSA).1 These patients do
not have overt daytime sleepiness and may
have little motivation for continuous positive
airway pressure (CPAP) therapy, the most
effective treatment for OSA. Symptomatic
OSA is an established independent risk
factor for arterial hypertension2 and has
been linked to atrial ﬁbrillation (AF)3 and to
sudden cardiac death (SCD).4 OSA, AF and
SCD may occur concomitantly and are of
considerable epidemiological interest, poten-
tially leading to morbidity and mortality.
Effective treatment with CPAP might prevent
progression and/or recurrence of AF and
factors leading to SCD. While there is good
evidence for this relationship in symptomatic
patients with moderate to severe OSA, no
data is available from randomised controlled
trials (RCTs) on this association in patients
with minimally symptomatic OSA.
OSA is associated with electrical and mech-
anical atrial remodelling.5 OSA severity has
been shown to be signiﬁcantly associated
with prolonged signal-averaged P-wave dur-
ation (SAPWD) and CPAP therapy is believed
Strengths and limitations of this study
▪ This is the first randomised controlled trial evalu-
ating the effect of continuous positive airway
pressure (CPAP) on ECG risk markers for atrial
fibrillation and sudden cardiac death in minimally
symptomatic obstructive sleep apnoea (OSA).
▪ The Multicentre Obstructive Sleep Apnoea
Interventional Cardiovascular (MOSAIC) rando-
mised trial was a rigorously planned and per-
formed study aimed at giving clinicians a better
foundation for treatment decision in the many
patients with OSA lacking overt daytime sleepi-
ness. However, the presented analysis was not
the primary objective of the MOSAIC trial.
▪ Adherence to CPAP is usually an issue in
patients with minimally symptomatic OSA.
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to be able to reverse atrial remodelling, as it signiﬁcantly
reduced SAPWD6 and P-wave dispersion (Pd)7 in
patients with moderate-to-severe OSA.
In patients with moderate to severe symptomatic OSA,
2 weeks of CPAP withdrawal led to signiﬁcant lengthen-
ing of QTc and Tpeak-to-Tend (TpTe) intervals in a ran-
domised trial by Rossi et al.8
It is unclear if there are similar effects of CPAP in
patients with minimally symptomatic OSA to guide
therapeutic decisions. To answer this question, we inves-
tigated the hypothesis that CPAP improves ECG risk
markers of AF and SCD in patients with minimally symp-
tomatic OSA and analysed ECG data from a subset of
patients in the Multicentre Obstructive Sleep Apnoea
Interventional Cardiovascular (MOSAIC) RCT.
METHODS
Study design
Nine centres from the UK and one from Canada partici-
pated in the MOSAIC trial, which was conducted
between May 2006 and February 2010. In three centres
(Oxford, Taunton and Reading), 12-lead ECG measure-
ments were obtained at baseline and at 6 months. The
trial was performed according to the Declaration of
Helsinki, and was registered (ISRCTN34164388).
Study participants
Patients with minimally symptomatic OSA, who were
usually referred due to witnessed apnoeas or severe
snoring, were randomised to either 6 months of CPAP
therapy or standard care (SC). Eligibility criteria were as
follows: age between 45 and 75 years, proven OSA on
the diagnostic sleep study deﬁned as >7.5 oxygen desa-
turations of >4% per hour (Oxygen Desaturation Index
(ODI) >7.5/h) in the baseline sleep study, and no
history of excessive daytime sleepiness or daytime symp-
toms of OSA that would have warranted CPAP therapy
initiation. Patients were not eligible for inclusion if they
had been previously diagnosed with ventilatory failure,
Cheyne-Stokes breathing, or blood pressure >180/
110 mm Hg. Patients with previous exposure to CPAP, a
current heavy goods vehicle or public service vehicle
driver license, a history of any sleep-related accident, or
disability precluding informed consent or compliance
with the protocol were also excluded. Cardiovascular
disease was not an exclusion criterion. All randomised
patients gave written informed consent.
Sleep study
Diagnosis of OSA was made after a one-night,
in-hospital, respiratory polygraphy as standard in the par-
ticipating centres. The severity of OSA was quantiﬁed as
the number of oxygen desaturations >4% per hour of
study (ODI). Subjective daytime sleepiness was assessed
using the Epworth Sleepiness Scale (ESS).9 Objective
sleepiness was assessed using one Oxford Sleep
Resistance test administered at the same time of the day
(Stowood Scientiﬁc Instruments Oxford, UK), which
evaluates the ability to stay awake for 40 min in a quiet,
darkened room. For consistency purposes across the
three centres, a second ambulatory pulse-oximetry
recording (Konica-Minolta Inc, Osaka, Japan) was per-
formed at baseline and at 6 months in all eligible
patients, and used as the trial ODI values. Patients were
then informed in detail about possible pros and cons of
CPAP. Patients with an ESS above the conventional
upper normal limit (9) were included, if suitable for
patients.
Randomisation
Parallel randomisation was performed by telephoning
the Medical Research Council Clinical Trials Unit. The
computer-generated allocation sequence with 1:1 ratio
incorporated minimisation for OSA severity, as assessed
by ODI (above or below 20/h), Pocock cardiovascular
risk score10 (above or below 40), and participating
centre.
Continuous positive airway pressure
Patients allocated to CPAP were instructed in the use of
an auto-adjusting CPAP machine (Autoset S8, ResMed,
Abingdon, UK) by trained staff who were not involved in
outcome assessments or data analysis. After 6 months,
CPAP usage was downloaded from the machine.
Standard care
Patients randomised to SC were instructed to continue
their current medication. No speciﬁc advice regarding
diet and lifestyle was given.
ECG
All patients were instructed to abstain from caffeine,
alcohol or tobacco at baseline and at 6 months
follow-up. Participants rested for 5 min in the supine
position before measurements, and room temperature
and lighting were kept constant. Standard commercially
available 12-lead ECG devices were used in all centres.
Paper-speed was set at 25 mm/s and amplitude at
10 mm/s. All measurements of ECG intervals were per-
formed using a dedicated ECG analysis calipre software
(DatInf Measure 2.1d, DatInf GmbH, Tübingen,
Germany) ofﬂine by the same investigator (CS), who
was not aware of the randomisation sequence or other
patient-speciﬁc data. The means of all available consecu-
tive heart cycles (three in the majority of cases) were
used in all 12 leads for computation of ECG markers.
The ECG indices were deﬁned as follows: P wave: the
onset of the P wave was deﬁned as the point of ﬁrst
detectable upward or downward slope from the isoelec-
tric line for positive or negative waveforms, respectively.
Return to the isoelectric line was considered as the end
of the P wave. Pmax/Pmin was deﬁned as the longest/
shortest mean value of consecutive heart cycles in any of
the 12 leads. Pd was deﬁned as the difference between
Pmax and Pmin. The PQ interval was deﬁned as the
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point from the beginning of the P wave to the ﬁrst part
of the QRS complex. The QT interval was deﬁned as the
time from the onset of the QRS complex to the cutting
point of the tangent to the downward slope of the T
wave and the isoelectric line. QTmax/QTmin was
deﬁned as the longest/shortest mean value of consecu-
tive heart cycles in any of the 12 leads. QT dispersion
was deﬁned as the difference between QTmax and
QTmin. The TpTe interval was deﬁned as the time from
the peak of the T wave to the cutting point of the
tangent to the downward slope of the T wave and the
isoelectric line. TpTe/QT ratio was used as a measure of
dispersion of repolarisation,11 and calculated as mean
TpTe divided by mean QT (from all leads). QT and
TpTe intervals were corrected for heart rate using
Bazett’s formula.12
Data analysis
Endpoints were the absolute changes in P wave disper-
sion, QT dispersion, heart rate, Pmean, Pmax, Pmin,
QTmean, QTcmean, QTmax, QTmin, TpTec and TpTe/
QT ratio over follow-up. In subgroup analyses, we com-
pared the effects of using CPAP >4 or ≤4 h/night against
control on each outcome, and the effect of CPAP in
patients with ODI >20 vs <20 at baseline. The effect of
CPAP on QTc and TpTec intervals was compared
between patients with QTc intervals ≥ or <430 ms at base-
line and with TpTec intervals ≥ or <90 ms at baseline.
Values are presented as mean (SD) unless otherwise
stated. Statistical analysis was performed with STATAV.13
for Windows (STATA Corporation, College Station,
Texas, USA). Treatment effects were estimated using
multiple linear regression adjusting for allocation group,
the minimisation variables, and the baseline value of the
corresponding outcome. The effect of CPAP in different
subgroups was assessed by adding a treatment-by-
subgroup interaction term to each model. All analyses
were performed using the intention-to-treat principle
and a two-sided p value of <0.05 was considered to be
statistically signiﬁcant.
RESULTS
Trial profile and patient characteristics
Figure 1 shows the trial proﬁle; 391 patients were initially
randomised in the 10 participating centres of the
MOSAIC trial. In the three centres (Oxford, Reading,
Taunton) in which 12-lead ECGs measurements were
performed, 303 patients were randomised. Of these, ﬁve
patients were lost to follow-up, three withdrew and one
patient died. In 21 patients, no analysable ECG data at
baseline were available, mostly due to AF (5 patients in
Figure 1 Study flow.
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CPAP group, 8 patients in SC group). In 23 patients no
analysable ECG data at follow-up were available due to
several reasons; 2 of them in the SC group had ventricu-
lar bigeminy. No other arrhythmias were recorded.
Thus, data from 250 patients were available for analysis.
Baseline patient characteristics were similar between
treatment groups (table 1). Data on the main outcomes
in MOSAIC are published elsewhere.13 There was no evi-
dence of any signiﬁcant differences in our subset of
patients when compared with the original study in the
treatment effects from CPAP on either ODI or ESS.13
Median (IQR) CPAP usage was 2.7 h/night (0.5, 4.9); 36
patients (28%) in the CPAP group did not use their
CPAP device at all.
Baseline analysis
There was no correlation between OSA severity (ODI)
and any of the analysed ECG risk markers at baseline.
Effect of CPAP on ECG risk markers for AF and SCD
Table 2 shows ECG interval times at baseline and at
follow-up. There were no relevant differences between
the two groups at baseline. No treatment effect of CPAP
on ECG risk markers for AF and SCD was found when
compared with SC.
Subgroup analyses
Treatment effects in patients who used their CPAP for at
least 4 h/night did not differ from those in patients
using their CPAP device for <4 h/night. There were no
differences in CPAP treatment effects on ECG markers
in patients with an ODI at baseline >20/h versus those
with an ODI ≤20/h. Moreover, patients with QTc inter-
vals at baseline ≥430 ms (15 in CPAP group, 5 in control
group) did not signiﬁcantly differ in terms of CPAP
treatment effect on QTc at follow-up from patients with
QTc intervals at baseline ≤430 ms, and the same was
true in patients having a TpTec interval at baseline
greater than 90 ms (13 in CPAP group, 18 in control
group).
DISCUSSION
This is the ﬁrst RCT providing data on the effect of
CPAP on ECG risk markers for AF and SCD in patients
with minimally symptomatic OSA. We found no treat-
ment effect of CPAP on any of the evaluated ECG risk
markers.
The MOSAIC randomised trial, from which these data
were derived, was a rigorously planned and performed
study aimed at giving clinicians a better evidence base
for treatment decisions in the many patients with OSA
lacking overt daytime sleepiness. Although a previous
study showed adverse effects of CPAP withdrawal on
heart rhythm in symptomatic patients with moderate to
severe OSA,8 no data from randomised trials in minim-
ally symptomatic OSA patients have yet been available.
Effect of CPAP on ECG risk markers for AF
A prolonged P wave on the surface ECG represents
intra-atrial conduction slowing, while an increase in P
wave dispersion indicates heterogeneous intra-atrial and
interatrial conduction, providing a substrate that favours
re-entry mechanisms. These variables have been shown
to represent independent predictors for new onset AF
as well as for relapse of AF after catheter ablation.14 15
In a large retrospective cohort analysis, P wave disper-
sion >80 ms and Pmax >120 ms, were associated with
HRs for developing AF of 1.95 and 1.9, respectively.14
The prevalence of OSA among patients with AF is
reported to be as high as 32%16 to 56%.17 These high
prevalence rates must be considered carefully due to
different study populations and designs. Nevertheless,
clinicians should be aware of the potentially negative
effects of OSA on treatment success of AF. This might
be especially important for those patients undergoing
catheter ablation of AF given recent ﬁndings of a
meta-analysis by Qureshi et al,18 who found a 44% lower
risk of AF recurrence in patients with OSA who used
CPAP versus those who did not.
Table 1 Baseline characteristics
Standard care NCPAP
N 151 152
Age (years) 57.5 (7.4) 58.0 (7.1)
Males, n (%) 127 (84.1) 123 (80.9)
Body mass index
(kg/m2)
32.6 (5.6) 32.0 (5.4)
Waist/hip
circumference ratio
1.0 (0.1) 1.0 (0.1)
Never smoked, n (%) 57 (37.7) 55 (36.2)
Ex-smoker, n (%) 70 (46.6) 82 (53.9)
Current smoker, n (%) 24 (15.9) 15 (9.9)
ODI (median, IQR) 9.1 (4.6, 15.2) 9.9 (3.9, 17.4)
Epworth sleepiness
scale
8.4 (4.1) 8.5 (4.3)
Osler min (median,
IQR)
35 (22, 35) 35 (27, 35)
Diabetes mellitus,
n (%)
32 (21.2) 19 (12.5)
Angina pectoris, n (%) 16 (10.6) 7 (4.6)
Myocardial infarction,
n (%)
12 (7.9) 8 (5.3)
Atrial fibrillation, n (%) 8 (5.3) 5 (3.3)
Arterial hypertension,
n (%)
67 (44.4) 65 (42.8)
Antihypertensive
medication, n (%)
69 (45.7) 61 (40.1)
Cholesterol-lowering
medication, n (%)
44 (29.1) 45 (29.6)
Glucose-lowering
medication, n (%)
23 (15.2) 15 (9.9)
Diuretics, n (%) 29 (19.2) 26 (17.1)
Potassium (mmol/L) 4.0 (0.4) 4.0 (0.4)
Values are mean (SD) unless otherwise stated.
NCPAP, Nasal Continuous Positive Airway Pressure; ODI, Oxygen
Desaturation Index; OSLER, Oxford Sleep Resistance test.
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In the current study, the 95% CI for the treatment
effect of CPAP on P wave dispersion excludes a reduc-
tion >3.4 ms. Therefore, our results do not support
CPAP treatment in minimally symptomatic OSA patients
in terms of risk reduction for progression and/or recur-
rence of AF. Moreover, we have previously found no evi-
dence that 6 months of CPAP has an effect on left atrial
area as assessed by echocardiography in a subset of
MOSAIC patients.19 Thus, CPAP appears to have no
electrical and structural impact on the atria in patients
with minimally symptomatic OSA. For further analysis,
we compared whether there was a statistically signiﬁcant
different CPAP treatment effect on atrial ECG risk
markers in those patients, having had an initial ODI
>20/h when compared with those with an ODI <20/h.
However, no such group interaction was found.
Effect of CPAP on ECG risk markers for SCD
The QT interval is primarily a measure of ventricular
repolarisation, although it includes the QRS interval
and, hence, ventricular depolarisation too. An inherited,
as well as acquired, QT prolongation is often used as a
marker for risk assessment of SCD.20 Prolongation of
the TpTe interval, a measure of cardiac transmural dis-
persion of repolarisation, of the QT dispersion as a
marker of general repolarisation abnormality, and of the
TpTe/QT ratio, a measure of disproportional prolonga-
tion of global dispersion relative to the QT interval
aimed at minimising effects of varying heart rates, are as
well linked to an increased risk of SCD through
enhanced susceptibility to early and late afterdepolarisa-
tions.21 22 The Rotterdam QT project showed that a QTc
interval of more than 440 ms was associated with a 2.3
times higher risk for SCD when compared with a QTc
≤440 ms (95% CI 1.4 to 3.9).23
There is growing evidence of a role for OSA in the
occurrence of SCD. In a large longitudinal study, OSA
has been proposed as a novel risk factor for SCD.4
In that study, nocturnal hypoxaemia and the apnoea
hypopnea index (AHI) strongly predicted SCD inde-
pendent of well-established risk factors. While the
general population is least likely to die from sudden
death from cardiac causes during the sleeping hours, in
patients with OSA, sudden death from cardiac causes
peaked during the sleeping hours.24
In the current study, there was no difference in CPAP
treatment effect on QTc between patients with an ODI
≥20/h when compared with patients with an ODI <20/h.
Recently, a RCT evaluating the effect of CPAP on mea-
sures of cardiac repolarisation in symptomatic patients
with moderate to severe OSA showed a statistically and
clinically signiﬁcant prolongation of QTc and TpTec after
2 weeks of CPAP withdrawal.8 In the latter study, baseline
QTc and TpTec intervals were higher than in our study
(416.1 vs 397.8 and 114.7 vs 76.1 ms, respectively), and
this might be due to the fact that more severe patients
with OSA were included. In those patients, a 2-week with-
drawal of CPAP led to an increase of the QTc interval of
21.4 ms, 95% CI 11.3 to 31.6 ms, and the increase in the
length of the QTc interval was positively correlated with
the change in the severity of sleep disordered breathing
(AHI) (r=0.60, 95% CI 0.36 to 0.77, p<0.001).
Conversely, in the current study, the 95% CI for the treat-
ment effect of CPAP on QTc excludes a reduction
greater than 3.5 ms, which probably does not represent a
clinically signiﬁcant effect. It could be argued that in our
patient sample, due to low intervals of cardiac repolarisa-
tion at baseline, no further reduction through the use of
CPAP could be achieved. However, we did not ﬁnd larger
effects of CPAP treatment in patients with QTc intervals
at baseline greater than 430 ms, or TpTec intervals at
baseline greater than 90 ms.
Limitations
This study has some limitations. First, the presented ana-
lysis was not the primary objective of the MOSAIC trial,
Table 2 CPAP treatment effects on ECG risk markers for atrial fibrillation and sudden cardiac death
Standard care CPAP
Outcome N
Baseline
mean (SD)
Follow-up
mean (SD) N
Baseline
mean (SD)
Follow-up
mean (SD)
Treatment effect
(95% CI) P Value
Heart rate 122 65.4 (11.2) 64.7 (12.6) 128 65.1 (10.5) 64.0 (10.2) −0.4 (−2.4 to 1.7) 0.71
P wave max 119 106.6 (9.9) 106.8 (10.7) 126 108.3 (11.2) 108.1 (12.4) 0.0 (−2.4 to 2.5) 0.98
P wave mean 119 87.1 (8.0) 86.1 (8.2) 126 87.6 (8.6) 87.6 (10.0) 0.9 (−0.8 to 2.6) 0.32
P wave dispersion 119 41.9 (12.0) 43.4 (12.0) 126 42.6 (11.8) 43.3 (12.8) −0.4 (−3.4 to 2.7) 0.82
QTmax 118 400.3 (30.4) 402.4 (33.6) 126 406.3 (34.6) 408.8 (35.1) 1.5 (−4.3 to 7.3) 0.61
QTmean 118 382.1 (28.7) 384.4 (30.6) 126 387.5 (31.4) 389.8 (30.4) 0.9 (−3.9 to 5.7) 0.72
QTcmean* 118 395.1 (20.2) 395.3 (21.0) 126 400.3 (24.6) 399.8 (25.6) 0.9 (−3.5 to 5.4) 0.68
QT dispersion 118 41.5 (15.4) 41.0 (17.1) 126 44.6 (17.8) 43.7 (16.8) 1.8 (−2.3 to 5.8) 0.39
PQ 114 155.9 (24.1) 154.3 (23.6) 125 156.3 (26.9) 157.5 (26.6) 2.4 (−2.1 to 7.0) 0.30
TpTe/QT 122 0.2 (0.0) 0.2 (0.0) 128 0.2 (0.0) 0.2 (0.0) 0.0 (−0.0 to 0.0) 0.89
TpTec* 122 76.2 (13.5) 75.1 (11.4) 128 76.0 (14.4) 75.5 (13.2) 0.2 (−2.6 to 2.9) 0.92
Values are mean (SD). 95% CI of the difference between groups in change from baseline.
*Corrected for heart rate.
CPAP, continuous positive airway pressure.
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thus, our interpretations must be regarded as hypothesis-
generating rather than fully robust. Second, high
intraobserver and interobserver variability is usually
found when measuring ECG intervals. However, all mea-
surements were made ofﬂine by the same experienced
investigator, who was blinded to treatment allocation
and other patient data at the time of analysis. Third,
adherence to CPAP is usually an issue in patients with
minimally symptomatic OSA. Patients often feel no
obvious beneﬁt from therapy, while discomfort using the
device can negate any potential beneﬁt. Median usage
in the current study was 2.7 h/night. However, subgroup
analyses revealed no difference in CPAP treatment effect
on any ECG risk marker in the more compliant partici-
pants who used their CPAP device more than 4 h/night.
Conclusions
This is the ﬁrst RCT providing data to evaluate the effect
of CPAP on ECG risk markers for AF and SCD in
patients with minimally symptomatic OSA. We found no
evidence of a treatment effect of CPAP on any of the
investigated ECG risk markers.
Based on our results, there seems to be no justiﬁcation
for CPAP treatment in patients with minimally symptom-
atic OSA in an attempt to reduce arrhythmia risk.
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